TY - JOUR
T1 - The association between lipoprotein(a) levels and the development of cardiac allograft vasculopathy
AU - Abbas, Mohammed Tiseer
AU - Awad, Kamal
AU - Farina, Juan M M.
AU - Mahmoud, Ahmed K K.
AU - Pereyra, Milagros
AU - Scalia, Isabel G G.
AU - Kamel, Moaz A A.
AU - Baba Ali, Nima
AU - Alsidawi, Said
AU - Lester, Steven J J.
AU - Nkomo, Vuyisile T T.
AU - Patel, Parag C C.
AU - Sell-Dottin, Kristen A A.
AU - Rosenbaum, Andrew N.
AU - Lin, Grace
AU - Hardaway, Brian W W.
AU - Steidley, D․ Eric
AU - Scott, Robert L L.
AU - LeMond, Lisa M M.
AU - Rosenthal, Julie L L.
AU - Ayoub, Chadi
AU - Arsanjani, Reza
N1 - Publisher Copyright:
© 2024 National Lipid Association
PY - 2025/3/1
Y1 - 2025/3/1
N2 - Lipoprotein(a) [Lp(a)] has been established as an independent risk factor for cardiovascular diseases. However, its role in cardiac allograft vasculopathy (CAV) development remains controversial. In a retrospective cohort study of 385 patients who underwent heart transplant between 2001 and 2023, Lp(a) concentrations were compared between patients with and without clinically significant CAV (grade 0-1 vs 2-3). Preoperative Lp(a) concentrations were not significantly different between patients with and without CAV (14.0 vs 12.0 mg/dL, P = .42). High (≥50 mg/dL) Lp(a) values were not associated with CAV development on univariable or multivariable analysis (hazard ratio [HR] 1.009, 95% CI: 0.47-2.14, P = .9). A history of graft rejection was the only independent factor associated with CAV (HR 2.88, 95 % CI: 1.50-5.52, P = .001). Elevated Lp(a) levels were not associated with increased risk of CAV. The lack of a significant association between traditional risk factors and CAV underscores that CAV is not purely an atherosclerotic process and different pathophysiological mechanisms are involved.
AB - Lipoprotein(a) [Lp(a)] has been established as an independent risk factor for cardiovascular diseases. However, its role in cardiac allograft vasculopathy (CAV) development remains controversial. In a retrospective cohort study of 385 patients who underwent heart transplant between 2001 and 2023, Lp(a) concentrations were compared between patients with and without clinically significant CAV (grade 0-1 vs 2-3). Preoperative Lp(a) concentrations were not significantly different between patients with and without CAV (14.0 vs 12.0 mg/dL, P = .42). High (≥50 mg/dL) Lp(a) values were not associated with CAV development on univariable or multivariable analysis (hazard ratio [HR] 1.009, 95% CI: 0.47-2.14, P = .9). A history of graft rejection was the only independent factor associated with CAV (HR 2.88, 95 % CI: 1.50-5.52, P = .001). Elevated Lp(a) levels were not associated with increased risk of CAV. The lack of a significant association between traditional risk factors and CAV underscores that CAV is not purely an atherosclerotic process and different pathophysiological mechanisms are involved.
KW - Cardiac allograft vasculopathy
KW - Coronary angiography
KW - Coronary artery disease
KW - Heart transplant
KW - Lipoprotein(a)
UR - https://www.scopus.com/pages/publications/85217405006
UR - https://www.scopus.com/inward/citedby.url?scp=85217405006&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2024.12.011
DO - 10.1016/j.jacl.2024.12.011
M3 - Article
AN - SCOPUS:85217405006
SN - 1933-2874
VL - 19
SP - 364
EP - 368
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 2
ER -